What medical conditions prompted sapropterin investigation?

Primary Condition: Phenylketonuria (PKU)

Sapropterin (Kuvan), a synthetic form of tetrahydrobiopterin (BH4), was first investigated for phenylketonuria (PKU), a genetic disorder where phenylalanine hydroxylase deficiency prevents breakdown of the amino acid phenylalanine, leading to toxic buildup in blood and brain.[1] Clinical trials focused on PKU patients over age 4 whose diet couldn't fully control levels, showing sapropterin reduced phenylalanine by enhancing residual enzyme activity.[2]

How It Works in PKU

As a cofactor for phenylalanine hydroxylase, sapropterin restores partial enzyme function in responsive patients (about 20-50% of cases), allowing phenylalanine tolerance without strict low-protein diets.[1][3] FDA approval in 2007 targeted hyperphenylalaninemia due to tetrahydrobiopterin-responsive PKU.[2]

Expansion to Hyperphenylalaninemia

Investigations extended to BH4-responsive hyperphenylalaninemia variants, including milder forms and those linked to partial BH4 synthesis defects, where sapropterin addresses cofactor shortages beyond classic PKU.[1][4]

Later Approvals for Other Disorders

- Alkaptonuria: Orphan drug status and trials explored sapropterin's role in homogentisate oxidation, prompted by the disorder's joint damage from unmetabolized homogentisic acid buildup.[5]
- MOHA (Tetrahydrobiopterin-Responsive Hyperphenylalaninemia): Approved in 2022 for this BH4 deficiency subtype, based on studies confirming responsiveness.[2]

No major investigations for unrelated conditions like autism or cardiovascular disease led to approvals, despite early off-label interest.[6]

Sources
[1] DrugPatentWatch.com - Sapropterin
[2] FDA Label - Kuvan
[3] NEJM - Sapropterin Trial in PKU (2007)
[4] J Inherit Metab Dis - BH4 Responsive Hyperphenylalaninemia
[5] ClinicalTrials.gov - Sapropterin in Alkaptonuria
[6] BioMarin Pipeline Overview